We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Snibe Diagnostic’s Maglumi SARS-CoV-2 S-RBD IgG Test Receives CE Mark

By LabMedica International staff writers
Posted on 05 Aug 2020
Snibe Diagnostic (Shenzhen, China) has received the CE mark for its fully automated quantitative serology test for detecting IgG antibodies against SARS-CoV-2S-RBD, the receptor-binding domain of S protein.

The test, called Maglumi SARS-CoV-2 S-RBD IgG, is designed for the quantitative detection of antibodies to the receptor-binding domain of the S protein, which are believed to neutralize the coronavirus and are an effective measure of immunity as compared to antibodies that target other SARS-CoV-2 proteins. More...
According to Snibe, the test has 99.6% specificity and 100% sensitivity at 15 days following the onset of symptoms for COVID-19, thus providing more accurate results. A strong correlation to neutralizing antibodies ensures better clinical management.

The test can be run on the company’s Maglumi CLIA systems, including the Maglumi X8 immunoassay analyzer which can run up to 600 tests per hour. More than 13,000 Maglumi CLIA system installations across the world pave the way for wide availability of the test. Snibe has confirmed that it is ready to ship the Maglumi SARS-CoV-2 S-RBD IgG test worldwide.

Related Links:
Snibe Diagnostic


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.